Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SunHo Starts Trial of Dual Immunocytokine Therapy for Solid Tumor Cancers

publication date: Jul 7, 2022

SunHo BioPharmaceutical of Nanjing started Phase I/II trials of two novel immunocytokines in patients with locally advanced or metastatic malignant tumors. Immunocytokines are antibody-cytokine fusion proteins with potential to localize on tumor lesions and activate anticancer immunity at the site of disease. The two candidates being tested are IAP0971, a PD1-IL15 immunocytokine. and IAE0972, an EGFR-IL10 immunocytokine. SunHo is developing a portfolio of 14 novel immunocytokines and bifunctional antibody fusion proteins for cancer immunotherapy and autoimmune diseases. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital